STUDY TYPE: Diagnostic (exploratory cohort). LEVEL OF EVIDENCE: 2b. OBJECTIVE: To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history. PATIENTS AND METHODS: Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates. RESULTS: In all, 624 participants were evaluated, including 382 (61.2%) African-American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score > or =7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason > or =7 prostate cancer vs 15.2% in all other participants (P < 0.001). CONCLUSION: The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These results support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men.
STUDY TYPE: Diagnostic (exploratory cohort). LEVEL OF EVIDENCE: 2b. OBJECTIVE: To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history. PATIENTS AND METHODS: Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates. RESULTS: In all, 624 participants were evaluated, including 382 (61.2%) African-American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score > or =7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason > or =7 prostate cancer vs 15.2% in all other participants (P < 0.001). CONCLUSION: The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These results support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men.
Authors: Brent V Yanke; Brett S Carver; Fernando J Bianco; Walter J Simoneaux; Dennis D Venable; Isaac J Powell; James A Eastham Journal: BJU Int Date: 2006-10 Impact factor: 5.588
Authors: Dipen J Parekh; Donna Pauler Ankerst; Betsy A Higgins; Javier Hernandez; Edith Canby-Hagino; Timothy Brand; Dean A Troyer; Robin J Leach; Ian M Thompson Journal: Urology Date: 2006-12 Impact factor: 2.649
Authors: Donna Pauler Ankerst; Jack Groskopf; John R Day; Amy Blase; Harry Rittenhouse; Brad H Pollock; Cathy Tangen; Dipen Parekh; Robin J Leach; Ian Thompson Journal: J Urol Date: 2008-08-15 Impact factor: 7.450
Authors: Veda N Giri; Jennifer Beebe-Dimmer; Mark Buyyounouski; Andre Konski; Steven J Feigenberg; Robert G Uzzo; Gerald Hanks; Andrew K Godwin; David Y T Chen; Robert Gordon; Terrence Cescon; Susan Raysor; Deborah Watkins-Bruner Journal: J Urol Date: 2007-09-17 Impact factor: 7.450
Authors: Ian M Thompson; Donna Pauler Ankerst; Chen Chi; Phyllis J Goodman; Catherine M Tangen; Scott M Lippman; M Scott Lucia; Howard L Parnes; Charles A Coltman Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544
Authors: Yuanyuan Liang; Jamie C Messer; Christopher Louden; Miguel A Jimenez-Rios; Ian M Thompson; Hector R Camarena-Reynoso Journal: Urol Oncol Date: 2012-02-03 Impact factor: 3.498
Authors: Michael Kongnyuy; Abhinav Sidana; Arvin K George; Akhil Muthigi; Amogh Iyer; Michele Fascelli; Meet Kadakia; Thomas P Frye; Richard Ho; Francesca Mertan; M Minhaj Siddiqui; Daniel Su; Maria J Merino; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: Urol Oncol Date: 2016-02-20 Impact factor: 3.498
Authors: Andreas N Strobl; Andrew J Vickers; Ben Van Calster; Ewout Steyerberg; Robin J Leach; Ian M Thompson; Donna P Ankerst Journal: J Biomed Inform Date: 2015-05-16 Impact factor: 6.317
Authors: Sonja Grill; Mahdi Fallah; Robin J Leach; Ian M Thompson; Stephen Freedland; Kari Hemminki; Donna P Ankerst Journal: J Urol Date: 2014-09-19 Impact factor: 7.450